Naloxone

According to a publication on StatPearls NCBI, Naloxone has held a unique position as the sole antidote to counteract the effects of opioids for over half a century. This life-saving drug has been readily accessible in parenteral formulations. Moreover, the availability of naloxone over-the-counter has facilitated its administration. Naloxone is specifically indicated for the treatment of opioid toxicity, primarily aimed at reversing the dangerous respiratory depression caused by opioid use. Its application is beneficial in cases of accidental or intentional overdose, as well as in instances of acute or chronic opioid toxicity. Common opioid overdoses that respond to naloxone treatment include those involving substances such as heroin, fentanyl, carfentanil, hydrocodone, oxycodone, methadone, and others.
Functionally, naloxone is a pure, competitive opioid antagonist that exhibits a strong affinity for the mu-opioid receptor. This property enables it to effectively reverse the effects of opioids. The onset of action varies depending on the route of administration but can be as rapid as one minute when administered intravenously (IV) or intraosseously (IO). Typically, an initial dose of 0.04 mg to 0.1 mg IV is administered. Notably, the FDA has recently approved an intranasal spray formulation (NAS), available in an autoinjector form. This device delivers 4 mg of naloxone and is designed for use by caregivers or family members.
For comprehensive information regarding monitoring recommendations and potential adverse effects, you can access the details through the provided link.